May 14, 2018
PRWEB
“FDNA, in collaboration with Cure Sanfilippo Foundation and Jonah’s Just Begun Foundation, announces the successful recognition of the facial phenotype of patients with Mucopolysaccharidosis IIIB (MPSIIIB), also called Sanfilippo syndrome type-B. This effort is part of the Genomics Collaborative®, an FDNA initiative to accelerate breakthroughs in precision medicine using deep learning and artificial intelligence.
Collaborators are using FDNA’s next-generation phenotyping (NGP) technologies to analyze patient clinical data and next-generation sequencing data. The outcome is real-time discovery of disease biomarkers, advancement of clinical and molecular technologies, and big genomic data. Together, this information will increase the ability of genetic testing to provide meaningful answers to difficult health questions.”
The article highlights FDNA’s groundbreaking research on Sanfilippo Syndrome, a rare genetic disorder. Through a genomics collaborative partnership, FDNA utilized its advanced AI-driven platform to analyze vast genomic datasets. Their findings provide new insights into the genetic underpinnings of Sanfilippo Syndrome, potentially paving the way for improved diagnostics and treatments. This partnership underscores FDNA’s commitment to leveraging artificial intelligence and genomics to address complex rare diseases, offering hope to affected individuals and their families by driving forward the understanding and management of Sanfilippo Syndrome.
